MELVILLE, N.Y., July 13, 2016 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or the “Company")
(OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Ed Field, the Company’s President
of the Disc/Spine Division, is presenting at the 3rd Annual Regenerative Medicine Essentials Course, held by the Wake
Forest Institute for Regenerative Medicine in Winston Salem, NC. On Friday, July 15th, Mr. Field will deliver his
presentation entitled, "Getting to Market: Interactive case studies with discussions on clinical trial plans, regulatory
pathways and funding options,” which will include a case study on the development of the Company’s therapy for the treatment of
chronic lumbar disc disease.
The primary objective of the Regenerative Medicine Essentials Course is to provide a various state-of-the-art
review of the various aspects of regenerative medicine including background material, the key scientific component of the field of
regenerative medicine, ethical, economic and other issues important to regenerative medicine. This one-week course, taught by
prominent experts, provides attendees a foundation in the next evolution of modern health care.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily
involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and
metabolic disorders:
- Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous
(or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be
used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc
disease. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the
bone marrow and cryopreserving the cells. In an out patient procedure, BRTX-100 is to be injected by a physician into the
patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and
who potentially face the prospect of surgery.
- Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown
adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown
adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of
brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers
have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that
such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to
differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including
those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking
statements in this release are made as of the date hereof and the Company undertakes no obligation to update such
statements.
CONTACT: Email: ir@biorestorative.com
